Consistent with its ability to increase cardiac cAMP production,36,37 recombinant GLP-1 and its analogs have been shown to improve cardiac contractility in patients with heart failure.38,39 The cardiac effects of GLP-1R agonists have also been explored in both preclinical and clinical studies, primarily in non-diabetic scenarios with ischemia–reperfusion (I/R) injury and following MI.40–42 Such studies have produced both positive40 and neutral findings,43 reporting effects that may be either dependent or independent of the GLP-1R.36,37,44 The present study specifically sought to address the effects of GLP-1R agonism in a diabetic rodent with permanent coronary artery occlusion, in which, like in their human counterparts, dysfunction develops to a greater extent